Hinge Bio
Hinge Bio, Inc. - Taking antibodies to the next dimension
- Website
- hingebio.com
- Total Funding
- $30.0M
- Last Round
- $30.0M Series AJan 2025
- Rounds
- 1
About
Hinge Bio is developing GEM-DIMER™ antibody therapeutics for patients living with immune-mediated diseases and cancer.
Summary
Hinge Bio is a Biotech company. It has raised $30.0M in total across 1 round, most recently a $30.0M Series A round in Jan 2025. Investors include Point72 Asset Management, Ridgeback Capital and InVivium Capital.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jan 2025
Investors
Similar Companies
Altos Labs combines academic science and industry development to create medicines that restore ce...
BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Calico researches human aging using advanced technologies and model systems, applying that knowle...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Global biosimulation software and services company accelerating drug development for 2,000+ bioph...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/hinge-bio"><img src="https://indexed.vc/api/badge/company/hinge-bio" alt="Hinge Bio on Indexed.vc" width="260" height="76" /></a>